ERYTECH announces enrollment of first patient in Phase II study of eryaspase in pancreatic cancer Post author:admERY Post published:July 28, 2014 Post category:Newsroom ERYTECH announces the enrollment of the first patient in its Phase II study with eryaspase in second line treatment of patients affected by pancreatic cancer. You Might Also Like ERYTECH receives authorization to start its Phase II clinical study in pancreatic cancer May 6, 2014 ERYTECH announces plans to conduct registered initial public offering in the United States July 28, 2015 ERYTECH to Host on September 22, 2020 Second Quarter 2020 Conference Call and Business Update September 16, 2020
ERYTECH announces plans to conduct registered initial public offering in the United States July 28, 2015
ERYTECH to Host on September 22, 2020 Second Quarter 2020 Conference Call and Business Update September 16, 2020